SCHEMBL264386

SCHEMBL264386

Cc1cccc2c(CNC(=O)c3ccc4nc(C(C)(C)C(F)(F)F)ccc4c3)ccnc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.38
PIK3CD O00329 1/20 0.38
GAA P10253 2/20 0.37
GLA P06280 1/20 0.37
TP53 P04637 1/20 0.37
KLKB1 P03952 2/20 0.37
KLK1 P06870 2/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
TTK P33981 1/20 0.37
MAPT P10636 2/20 0.36
DGAT2 Q96PD7 1/20 0.36
BRAF P15056 1/20 0.36
CSNK1D P48730 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263858 0.88 SMN1; SMN2 (0.43) SMN1; SMN2LMNAALDH1A1PKMHTT
SCHEMBL264812 0.85 TRPV1 (0.39) SMN1; SMN2LMNAALDH1A1PKMHTT
SCHEMBL263302 0.84 EGLN1 (0.39) SMN1; SMN2LMNAHTTKLKB1ADORA2A
SCHEMBL263771 0.83 EGLN1 (0.40) SMN1; SMN2LMNAHTTKLKB1ADORA2A
SCHEMBL263695 0.81 SMN1; SMN2 (0.57) SMN1; SMN2LMNAALDH1A1PKMHTT
SCHEMBL265347 0.80 NAMPT (0.43) DGAT2
SCHEMBL1840774 0.75 ROCK2 (0.45) SMN1; SMN2LMNAALDH1A1HTTGAA
SCHEMBL1840633 0.74 HPGD (0.41) SMN1; SMN2LMNAALDH1A1HTTTP53
SCHEMBL264842 0.73 NAMPT (0.43) DGAT2
SCHEMBL2008896 0.73 TP53 (0.38) LMNAALDH1A1TP53MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-8134004-B2 Substituted N-bicyclicalkyl bicycliccarboxyamide compounds PFIZER INC. (US) 2012-03-13 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS PFIZER INC 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253740-A1 SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS OPRL1, CNR1, TRPV1 SMN1; SMN2 1166/4885LMNA 2567/4885ALDH1A1 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.